SAB Biotherapeutics Launches Major Equity Financing Offering

SAB Biotherapeutics ( (SABS) ) just unveiled an announcement.

On March 17, 2026, SAB Biotherapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 19,324,677 shares of common stock and pre-funded warrants for up to 2,753,246 additional shares, all sold by the company at a public price of $3.85 per share or $3.8499 per pre-funded warrant, with a 30-day option for underwriters to buy up to 3,311,688 additional shares. The offering, expected to close on March 19, 2026 under an effective shelf registration, is anticipated to generate about $69.7 million in net proceeds, or $81.7 million if the overallotment is fully exercised, providing SAB with substantial capital to advance its SAB-142 clinical program, manufacturing, regulatory and operational activities, and general corporate purposes.

SAB BIO announced on March 17, 2026 that Jefferies, UBS Investment Bank, Citigroup, and Barclays are acting as joint bookrunners, with Chardan as lead manager, for this equity raise. By bolstering its balance sheet through a sizable primary equity issuance, the company is reinforcing its ability to fund ongoing and planned trials in type 1 diabetes and other autoimmune indications, a move that may dilute existing shareholders but supports its longer-term growth and development pipeline.

The most recent analyst rating on (SABS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.

Spark’s Take on SABS Stock

According to Spark, TipRanks’ AI Analyst, SABS is a Neutral.

The score is held back primarily by weak financial performance (collapsed revenue, continued operating losses, and ongoing cash burn). Technicals are also soft in the near term despite oversold readings. These are partially offset by a low headline P/E and positive corporate developments around SAB-142’s clinical progress and funding/strategy updates, though dilution risk remains via the ATM facility.

To see Spark’s full report on SABS stock, click here.

More about SAB Biotherapeutics

SAB Biotherapeutics, Inc., also known as SAB BIO, is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency human immunoglobulin G therapies for immune and autoimmune disorders. Leveraging proprietary transchromosomic cattle technology, its lead candidate SAB-142 targets autoimmune type 1 diabetes and is in a registrational Phase 2b trial in newly diagnosed Stage 3 patients.

Average Trading Volume: 496,835

Technical Sentiment Signal: Buy

Current Market Cap: $188.5M

For detailed information about SABS stock, go to TipRanks’ Stock Analysis page.